SINGAPORE, May 10, 2011 /PRNewswire/ -- Novus Scientific Pte. Ltd today announced that it will be exhibiting at EHS 2011 in Ghent, Belgium ahead of receiving its anticipated CE Mark approval this year for TIGR® Matrix Surgical Mesh, the World's 1st Long-Term Resorbable Synthetic Mesh.
To mark the occasion, a special presentation has been organized on Wednesday May 11th 2011 at the Zebrastraat venue in Ghent (http://www.novusscientific.com/events/), featuring renowned surgeons; Dr. Frederik Berrevoet, Ghent University Hospital, who will lecture on "From polypropylene to TIGR® Matrix: towards the 'ideal' mesh" and Dr. Bruce Ramshaw, Halifax Health Medical Center, Daytona, FL, who will lecture on "Permanent mesh complications: How TIGR® Matrix can help". Henrik Magnusson, co-inventor of TIGR® Matrix will deliver a lecture on the design and properties of long-term resorbable synthetic mesh and answer questions from the audience on how this new class of 100% resorbable synthetic mesh is filling an important gap between biologics and permanent synthetics.
"EHS 2011 marks an important milestone for TIGR® Matrix and for Novus Scientific with presentation of the preliminary one year data from the First in Man clinical study. In this past year we have seen the growing acceptance by many surgeons of TIGR® Matrix as a new approach to soft tissue repair. With the anticipated approval of the CE Mark, we are excited to be able to offer TIGR® Matrix to leading surgeons and hospitals across Europe in the not too distant future," said Thomas Engstrom, CEO & President of Novus Scientific."We look forward to establishing a presence in Europe and to introducing TIGR® Matrix to the leading hernia centers once we attain the anticipated CE Mark. We have a major multicenter randomized controlled study planned with key opinion leaders and are very encouraged by the amount of attention TIGR® Matrix is receiving," said Tom Haeleydt, responsible for Sales & Marketing EMEA.TIGR® Matrix is the World's 1st Long-Term Resorbable Synthetic Mesh. US FDA cleared TIGR® Matrix Surgical Mesh for use in reinforcement of soft tissues where weakness exists in February 2010.
About Novus ScientificNovus Scientific (www.novusscientific.com) is an innovator in the development and commercialization of resorbable synthetic medical devices. Global HQ is in Singapore while European Headquarters and the core R&D function are in Uppsala, Sweden. The company's roots are Swedish as all the founders of Novus Scientific are previous owners / senior managers / members of the soft tissue-engineering project within Uppsala-based, Radi Medical Systems AB (now owned by St. Jude Medical Inc). The US Division, Novus Scientific, Inc. is headquartered near Boston, one of the world's foremost medical research cities. From this hub, Novus Scientific, Inc. will distribute TIGR® Matrix Surgical Mesh throughout the United States, Canada, and Latin America.
TIGR® is a trademark of Novus Scientific Pte. LtdCONTACT:
|SOURCE Novus Scientific Pte. Ltd|
Copyright©2010 PR Newswire.
All rights reserved